• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Ionis Pharmaceuticals (IONS) Reports Fresh Phase 3 Wins, Is The 49% Discount Justified?

    Simply Wall St·09/27/2026 14:14:53
    Listen to the news

    Ionis Pharmaceuticals stock reaction to fresh Phase 3 data

    Ionis Pharmaceuticals (IONS) is back in focus after back to back positive Phase 3 readouts for sefaxersen in IgA nephropathy and ulefnersen in FUS linked ALS reshaped how investors view its drug pipeline.

    For Ionis Pharmaceuticals, that clinical momentum is arriving after a tough stretch in the market. The share price is down about 44% year to date and the 1 year total shareholder return has declined roughly 31%, even though 5 year total shareholder return remains positive at about 33%.

    The latest 1 day share price return of 1.57% suggests that traders are starting to reassess the risk profile as the Phase 3 data lands. However, the 30 day share price return falling about 27% and the 90 day share price return down roughly 45% show that sentiment had reset sharply before these updates.

    Compare Ionis Pharmaceuticals' clinical swing with other potential rebound stories by reviewing the hand picked 32 high quality undervalued stocks that combine solid fundamentals with compressed valuations.

    Ionis Pharmaceuticals now appears to be a company with growing clinical proof, yet its share price has been heavily marked down. Are investors still paying too much for that pipeline, or has sentiment pushed it too far in the other direction?

    Most Popular Narrative: 49% Undervalued

    At a last close of $44.50 against a fair value estimate of $88.00, the prevailing narrative frames Ionis Pharmaceuticals as heavily marked down relative to its modeled future cash flows under a 7.77% discount rate.

    The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are described as potential drivers of sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.

    Expanding addressable patient populations from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, is cited as positioning Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

    See why 16 investors see Ionis Pharmaceuticals as 49% undervalued.

    Result: Fair Value of $88.00 (UNDERVALUED)

    Still, Ionis Pharmaceuticals faces real swing factors, including regulatory setbacks on late stage programs as well as price pressure as Olezarsen moves into broader severe hypertriglyceridemia use.

    Find out about the key risks to this Ionis Pharmaceuticals narrative.

    Next Steps

    With sentiment this mixed around Ionis Pharmaceuticals, it helps to move quickly, review the core data, and decide where you stand. Start by weighing the 2 key rewards.

    Looking for more Ionis Pharmaceuticals style investment ideas?

    If you want to keep sharpening your process beyond Ionis Pharmaceuticals, broaden your watchlist with focused stock ideas that match clear risk and reward profiles.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.